Q-omics provides the consensus-scored TMSB4XP4 profile across patient tissues and cancer cell-line models. TMSB4XP4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TMSB4XP4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TMSB4XP4 RNA expression shows 16,725 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where TMSB4XP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMSB4XP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMSB4XP4 survival associations across molecular data types. TMSB4XP4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMSB4XP4 RNA expression–survival associations across cancer types. High TMSB4XP4 expression shows unfavorable associations in LGG, LIHC and UVM, but favorable associations in SKCM, CESC and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TMSB4XP4 RNA expression.
This table summarizes TMSB4XP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMSB4XP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMSB4XP4 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, THCA, HNSC and STAD. The KIRC box plot shows higher TMSB4XP4 RNA expression in tumor versus normal tissue (log2 FC = +0.773, t-test p < 0.001).
This table shows molecular features associated with TMSB4XP4 in patient tissues and cancer cell lines. In patient samples, TMSB4XP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
